Results
NPS, pain
From baseline to week 15, soticlestat treatment was associated with a mean change in 24-hour pain intensity NPS score (95% confidence interval) of –0.75 (–1.55, 0.05) vs –0.41 (–1.41, 0.59) in the placebo group, resulting in a non-significant placebo-adjusted difference of –0.34 (–1.55, 0.88; 